Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €21.07 EUR
Change Today +0.79 / 3.90%
Volume 315.2K
IBAB On Other Exchanges
Symbol
Exchange
Stuttgart
EN Brussels
OTC US
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Open
€20.50
Previous Close
€20.28
Day High
€21.21
Day Low
€20.49
52 Week High
03/27/15 - €21.21
52 Week Low
03/27/14 - €7.95
Market Cap
603.7M
Average Volume 10 Days
64.8K
EPS TTM
€0.87
Shares Outstanding
28.7M
EX-Date
--
P/E TM
24.3x
Dividend
€0.17
Dividend Yield
--
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications SA operates as a cancer diagnostics and treatment equipment company in Belgium, the United States, and internationally. The company develops, manufactures, and supports medical devices and software solutions for cancer treatment by proton beam therapy. It operates in two segments, Proton therapy and Particle accelerators, and Dosimetry. The Proton therapy and Particle accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of Positron Emission Tomography or Single Photon Emission Computed Tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment offers measurement and quality assurance instruments for radiotherapy and medical imaging to enable the healthcare professionals to verify that equipment administers the planned dose to the targeted area. The company was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,037 Employees
Last Reported Date: 04/12/14
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: €615.0K
Compensation as of Fiscal Year 2013.

ion beam applications (IBAB) Key Developments

Ion Beam Applications, S.A. Reports Consolidated Annual Results for the Year of 2014

Ion Beam Applications, S.A. reported consolidated annual results for the year of 2014. For the year, the company reported total net sales of EUR 220,577,000 against EUR 212,512,000 a year ago. Profit Before Tax was EUR 17,173,000 against loss before tax of EUR 408,000 a year ago. Net result was EUR 24,294,000 against negative net result of EUR 1,011,000 a year ago. Total revenue impacted by low backlog conversion rate of Dosimetry.

Ion Beam Applications, S.A., 2014 Earnings Call, Mar 26, 2015

Ion Beam Applications, S.A., 2014 Earnings Call, Mar 26, 2015

Ion Beam Applications S.A. Signs Contract to Install First Proton Therapy Center in North China

Ion Beam Applications S.A. announced that it has received a significant upfront payment for a new contract with the Zhuozhou Jian Kang Qiao Investment Company Ltd, to establish a proton therapy center in Zhuozhou City, Hebei Province, China. The center will be the first Proton Therapy Center in North China, situated 30 minutes from Beijing and it is expected to treat up to 2,000 patients per year. The contract was signed at the end of 2014 and is worth more than EUR 80 million to IBA including the service contract. This does not impact the company`s guidance for 2014 given at the time of the third quarter results. IBA will equip the new center with its Proteus®PLUS multiroom system including five treatment rooms, four isocentricgantry treatment rooms and a fixedbeam treatment room. IBA will also provide all dosimetry equipment to ensure the safest and fastest commissioning of the center. The contract also includes an operations and maintenance agreement and it is anticipated that patients will be able to access proton therapy treatment at the center at the end of 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €21.07 EUR +0.79

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $48.29 USD +1.62
Analogic Corp $89.93 USD +0.06
Balchem Corp $56.58 USD -0.315
Quidel Corp $27.18 USD +0.66
Sumitomo Heavy Industries Ltd ¥795.00 JPY -14.00
View Industry Companies
 

Industry Analysis

IBAB

Industry Average

Valuation IBAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 4.9x
Price/Cash Flow 200.7x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit www.iba-worldwide.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.